• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Murphy Canyon Acquisition Corp.

    2/16/23 5:28:28 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MURF alert in real time by email
    SC 13D 1 formsc13d.htm

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)

     

    MURPHY CANYON ACQUISITION CORP.

    (Name of Issuer)

     

    Class A Common Stock, $0.0001 par value

    (Title of Class of Securities)

     

    626642 102

    (CUSIP Number)

     

    Anthony Giraulo

    Shaolin Capital Managment LLC

    Chief Financial Officer

    230 NW 24th Street Suite 603

    Miami, FL 33133

    Telephone: 212-433-4310

     

    (Name, Address and Telephone Number of Person Authorized to

    Receive Notices and Communications)

     

    February 13, 2022

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

     

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or other subject to the liabilities of that section of Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 626642 102

     

    1

    Names of Reporting Person.

     

    Shaolin Capital Management, LLC

    2

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ☐

    3

    SEC Use Only

     

    4

    Source of Funds (See Instructions)

     

    WC

    5

    Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) ☐

     

    6 Citizenship or Place of Organization
       
      Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7

    Sole Voting Power

     

    609,750 (1)

    8

    Shared Voting Power (see Item 5 below)

     

    0

    9

    Sole Dispositive Power

     

    609,750

    10

    Shared Dispositive Power (see Item 5 below)

     

    0

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    609,750 (1)

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐

     

    13

    Percent of Class Represented by Amount in Row (11)

     

    20.73% (2)

    14

    Type of Reporting Person

     

    OO

     

    (1)

    The securities to which this filing relates are held directly by (i) Shaolin Capital Partners Master Fund, LTD, a Cayman Islands exempted company, to which Shaolin Capital Management LLC, a Delaware limited liability company, (the "Investment Manager") serves as the investment manager and (ii) an sub-accounts (the "Managed Accounts") to which the Investment Manager serves as sub-advisor. Sponsor, LLC, and the Issuer.

    (2) Based on 2,941,728 Class A Common Shares outstanding as of February 16, 2022.

     

     

     

     

    SCHEDULE 13D

     

    This Schedule 13D is filed on behalf of Shaolin Capital Management, LLC, a Delaware limited liability company.

     

    Item 1. Security and Issuer

     

    Securities acquired: Class A common stock, $0.0001 par value (“Class A Common Shares”)

     

      Issuer: Murphy Canyon Acquisition Corp. (the “Issuer”)
        4995 Murphy Canyon Road, Suite 300
        San Diego, CA 92123

     

    Item 2. Identity and Background

     

    (a) This statement is filed by:

     

      (i) Shaolin Capital Management, LLC which is the holder of record of approximately 20.73% of the issued and outstanding Class A common shares).
         
      (ii) The securities to which this filing relates are held directly by (i) Shaolin Capital Partners Master Fund, LTD, a Cayman Islands exempted company, to which Shaolin Capital Management LLC, a Delaware limited liability company, (the "Investment Manager") serves as the investment manager and (ii) an sub-accounts (the "Managed Accounts") to which the Investment Manager serves as sub-advisor. Sponsor, LLC, and the Issuer..

     

    All disclosures herein with respect to any Reporting Person are made only by the Reporting Person. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

     

    (b) The address of the principal business and principal office is 230 NW 24th Street Suite 603 Miami, FL 33133

     

     

    (c) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (d) None of the Reporting Persons has, during the last five years, been a party to civil proceeding of a judicial administrative body of competent jurisdiction and, as a result of such proceeding, was, or is subject to, a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

     

    (e) Shaolin Capital Management is is a Delaware limited liability company.

     

    Item 3. Source and Amount of Funds or Other Consideration.

     

    The aggregate purchase price for the Common Shares currently beneficially owned by the Reporting Persons was $6,130,020. The source of these funds was the working capital of the Sponsor.

     

    Item 4. Purpose of the Transaction

     

    11,037,272 shares of common stock were tendered for redemption.As a result of the common stock tendered for redemption(11,037,272 shares of common stock were tendered for redemption) Shaolin Capital Management ownership percentage crossed 20% .

     

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 16, 2023 Shaolin Capital Management, LLC
         
      By: /s/ Anthony Giraulo
      Name:  Anthony Giraulo
      Title: Chief Financial Officer
         
    Date: February 16, 2023   /s/ Anthony Giraulo
        Anthony Giraulo

     

     
    Get the next $MURF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MURF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MURF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

    SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris

    9/22/23 9:01:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited

    SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil

    9/20/23 5:40:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Presidio Property Trust, Inc. Announces Establishment of a Special Committee of the Board and Exploration of Strategic Alternatives

    SAN DIEGO, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Presidio Property Trust, Inc. (NASDAQ:SQFT, SQFTP))) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today announced that its Board of Directors (the "Board") has established a Special Committee of the Board (the "Special Committee") to explore potential strategic alternatives focusing on maximizing stockholder value. The Special Committee is comprised solely of independent directors and is charged with exploring potential strategic alternatives, including, without limitation, a business combination involving the Company, a sale of all or part of the Company's assets, joint venture arrangements and/or

    9/13/23 8:30:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    $MURF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lewis-Hall Freda C

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/14/23 5:16:03 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mcnealey Jennifer Isacoff

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/5/23 5:20:25 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bligh James

    4 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Issuer)

    12/5/23 5:20:29 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURF
    SEC Filings

    View All

    SEC Form S-8 filed by Murphy Canyon Acquisition Corp.

    S-8 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    1/10/24 4:43:04 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Murphy Canyon Acquisition Corp.

    424B3 - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    12/18/23 4:14:52 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by Murphy Canyon Acquisition Corp.

    EFFECT - CONDUIT PHARMACEUTICALS INC. (0001896212) (Filer)

    12/18/23 12:15:16 AM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/12/24 12:51:14 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/8/24 1:15:17 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)

    SC 13G/A - CONDUIT PHARMACEUTICALS INC. (0001896212) (Subject)

    2/2/24 4:28:59 PM ET
    $MURF
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MURF
    Financials

    Live finance-specific insights

    View All

    Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination

    SAN DIEGO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Limited ("Conduit Pharmaceuticals"), a multi-asset clinical-stage disease-agnostic life science company providing an efficient model for compound development, and Murphy Canyon Acquisition Corp., a special purpose acquisition company (NASDAQ:MURF) ("MURF"), announced today the completion of the previously announced business combination (the "Transaction"). Conduit expects to commence trading on September 25, 2023, under ticker symbol "CDT" for its common stock on The Nasdaq Global Market and ticker symbol "CDTTW" for its warrants on The Nasdaq Capital Market.At the debut of trading, there will be a pro forma enterpris

    9/22/23 9:01:00 AM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited

    SAN DIEGO, CA / ACCESSWIRE / September 20, 2023 / Murphy Canyon Acquisition Corp. (NASDAQ:MURF) ("MURF" or "Murphy Canyon"), a special purpose acquisition company, announced today that at a special meeting of the MURF stockholders (the "Special Meeting") held today, MURF's stockholders voted in favor of the proposed business combination (the "Business Combination") with Conduit Pharmaceuticals Limited ("Conduit") and the related proposals. As a result, the completion of the Business Combination is expected to occur as soon as practicable, subject to the satisfaction or waiver of remaining closing conditions. Following the completion of the Business Combination, the newly combined company wil

    9/20/23 5:40:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate

    Presidio Property Trust, Inc. Announces Earnings for the Quarter Ended June 30, 2023

    SAN DIEGO, CA / ACCESSWIRE / August 14, 2023 / Presidio Property Trust, Inc. (NASDAQ:SQFT)(NASDAQ:SQFTP) (the "Company"), an internally managed, diversified real estate investment trust ("REIT"), today reported earnings for its quarter ended June 30, 2023.Quarter Ended June 30, 2023, Financial ResultsNet loss attributable to the Company's common stockholders for the three months ended June 30, 2023, was approximately $1,831,889, or $(0.15) per basic and diluted share, compared to a net loss of approximately $830,212, or $(0.07) per basic and diluted share for the three months ended June 30, 2022. The change in net income attributable to the Company's common stockholders was a result of: •An

    8/14/23 5:30:00 PM ET
    $MURF
    $SQFT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Real Estate Investment Trusts
    Real Estate